
Opinion|Videos|May 8, 2024
Key Results From the MajesTEC-1, MonumenTAL-1, and MagnetisMM-3 Trials
Sarah Rockwell, PharmD, BCOP, provides an overview of the safety and efficacy data of bispecific antibodies investigated in the MajesTEC-1, MonumenTAL-1, and MagnetisMM-3 trials, providing critical insights into the results of each study.
Advertisement
Episodes in this series

Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Fall 2025 Quiz: Test Your Pharmacy Knowledge!
2
Earlier Menopause, Reduced Cardiac Function Potentially Linked With Negative Impacts on Brain Health
3
FDA Approves Elinzanetant as First Nonhormonal Therapy for Menopause Vasomotor Symptoms
4
Menopause Care Varies by Provider, Highlighting Need for Standardized Education
5














































































































































































































